Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13

1 Oct 2024

Abstract excerpt

Biallelic loss of cyclin-dependent kinase 12 ( CDK12 ) defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. It remains unclear, however, whether CDK12 loss drives prostate cancer (PCa) development or uncovers pharmacologic vulnerabilities. Here, we show Cdk12 ablation in murine prostate epithelium is sufficient to induce preneoplastic lesions with lymphocytic infiltration. In allograft-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39368479
DOI: 10.1016/j.xcrm.2024.101758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13PMID 39368479Read ↗

<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalitySemantic proximity Read ↗

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read ↗

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Semantic proximity Read ↗

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.Semantic proximity Read ↗

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategiesSemantic proximity Read ↗

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressSemantic proximity Read ↗

Compromised CDK12 activity causes dependency on the non-essential spliceosome componentsSemantic proximity Read ↗

Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair PathwaysSemantic proximity Read ↗

Characterizing CDK12-Mutated Prostate CancersSemantic proximity Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

Summary data-based mendelian randomization and single-cell RNA sequencing analyses identify key genes associated with ubiquitination in prostate cancerSemantic proximity Read ↗

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.